PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO EVALUATE THE SYSTEMIC EXPOSURE OF GEFITINIB IN THE CYP2D6 ULTRARAPID METABOLIZERS AND EXTENSIVE METABOLIZERS.

被引：0
|
作者：
Chen, Y. [1 ]
Zhou, W. [1 ]
Tang, W. [1 ]
Zhou, D. [1 ]
Masson, E. [1 ]
机构：
[1] Astrazeneca, Waltham, MA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 101卷 / S1期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-021
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6
    M Desai
    J E Tanus-Santos
    L Li
    J C Gorski
    M Arefayene
    Y Liu
    Z Desta
    D A Flockhart
    The Pharmacogenomics Journal, 2003, 3 : 105 - 113
  • [22] Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6
    Desai, M
    Tanus-Santos, JE
    Li, L
    Gorski, JC
    Arefayene, M
    Liu, Y
    Desta, Z
    Flockhart, DA
    PHARMACOGENOMICS JOURNAL, 2003, 3 (02): : 105 - 113
  • [23] Safety and efficacy of atomoxetine in pediatric CYP2D6 extensive vs. poor metabolizers
    Allen, AJ
    Wernicke, J
    Dunn, D
    Kratochvil, C
    West, S
    Casat, C
    Harder, D
    Faries, D
    Laws, H
    Kelsey, DK
    Thomasson, H
    Heiligenstein, JH
    Potter, WZ
    Michelson, D
    BIOLOGICAL PSYCHIATRY, 2002, 51 (08) : 37S - 37S
  • [24] The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine
    Nguyen, Hoa Q.
    Callegari, Ernesto
    Obach, R. Scott
    DRUG METABOLISM AND DISPOSITION, 2016, 44 (10) : 1569 - 1578
  • [25] ENDOGENOUS CODEINE AND MORPHINE IN POOR AND EXTENSIVE METABOLIZERS OF THE CYP2D6 (DEBRISOQUINE/SPARTEINE) POLYMORPHISM
    MIKUS, G
    BOCHNER, F
    EICHELBAUM, M
    HORAK, P
    SOMOGYI, AA
    SPECTOR, S
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 268 (02): : 546 - 551
  • [26] High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies
    Naranjo, M. E. G.
    de Andres, F.
    Delgado, A.
    Cobaleda, J.
    Penas-Lledo, E. M.
    LLerena, A.
    PHARMACOGENOMICS JOURNAL, 2016, 16 (05): : 485 - 490
  • [27] High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies
    M E G Naranjo
    F de Andrés
    A Delgado
    J Cobaleda
    E M Peñas-Lledó
    A LLerena
    The Pharmacogenomics Journal, 2016, 16 : 485 - 490
  • [28] High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
    E M Peñas-Lledó
    P Dorado
    Z Agüera
    M Gratacós
    X Estivill
    F Fernández-Aranda
    A LLerena
    Molecular Psychiatry, 2011, 16 : 691 - 692
  • [29] Infant Dextromethorphan and Dextrorphan Exposure via Breast Milk From Mothers Who Are CYP2D6 Extensive Metabolizers
    Shum, Sara
    Yadav, Aprajita
    Fay, Emily
    Moreni, Sue
    Mao, Jennie
    Czuba, Lindsay
    Wang, Celine
    Isoherranen, Nina
    Hebert, Mary F.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (06): : 747 - 755
  • [30] High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
    Penas-LLedo, E. M.
    Dorado, P.
    Agueera, Z.
    Gratacos, M.
    Estivill, X.
    Fernandez-Aranda, F.
    LLerena, A.
    MOLECULAR PSYCHIATRY, 2011, 16 (07) : 691 - 692
12345